RU2513698C2 - Способ повышения качества жизни половозрелого животного - Google Patents
Способ повышения качества жизни половозрелого животного Download PDFInfo
- Publication number
- RU2513698C2 RU2513698C2 RU2011106036/10A RU2011106036A RU2513698C2 RU 2513698 C2 RU2513698 C2 RU 2513698C2 RU 2011106036/10 A RU2011106036/10 A RU 2011106036/10A RU 2011106036 A RU2011106036 A RU 2011106036A RU 2513698 C2 RU2513698 C2 RU 2513698C2
- Authority
- RU
- Russia
- Prior art keywords
- ppm
- animal
- composition
- quality
- life
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 136
- 238000000034 method Methods 0.000 title claims abstract description 115
- 239000000203 mixture Substances 0.000 claims abstract description 135
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 117
- 230000014509 gene expression Effects 0.000 claims abstract description 57
- 210000003205 muscle Anatomy 0.000 claims abstract description 30
- 210000000845 cartilage Anatomy 0.000 claims abstract description 25
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 24
- 230000036626 alertness Effects 0.000 claims abstract description 13
- 230000035899 viability Effects 0.000 claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 230000015572 biosynthetic process Effects 0.000 claims description 31
- 230000006378 damage Effects 0.000 claims description 30
- 235000019197 fats Nutrition 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 22
- 210000000988 bone and bone Anatomy 0.000 claims description 22
- 230000037353 metabolic pathway Effects 0.000 claims description 22
- 241000282326 Felis catus Species 0.000 claims description 21
- 230000006870 function Effects 0.000 claims description 21
- 230000032258 transport Effects 0.000 claims description 21
- 229920002527 Glycogen Polymers 0.000 claims description 20
- 229940096919 glycogen Drugs 0.000 claims description 20
- 230000023555 blood coagulation Effects 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 230000004044 response Effects 0.000 claims description 18
- 238000003786 synthesis reaction Methods 0.000 claims description 18
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 18
- 206010061218 Inflammation Diseases 0.000 claims description 16
- 230000004054 inflammatory process Effects 0.000 claims description 16
- 230000015556 catabolic process Effects 0.000 claims description 15
- 238000006731 degradation reaction Methods 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 230000034659 glycolysis Effects 0.000 claims description 15
- 230000004108 pentose phosphate pathway Effects 0.000 claims description 15
- 230000033616 DNA repair Effects 0.000 claims description 14
- 230000004110 gluconeogenesis Effects 0.000 claims description 14
- 230000002776 aggregation Effects 0.000 claims description 13
- 238000004220 aggregation Methods 0.000 claims description 13
- 230000001976 improved effect Effects 0.000 claims description 13
- 210000000118 neural pathway Anatomy 0.000 claims description 13
- 229930003427 Vitamin E Natural products 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- 230000010118 platelet activation Effects 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 229940046009 vitamin E Drugs 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 229960003080 taurine Drugs 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 229960004203 carnitine Drugs 0.000 claims description 8
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 8
- 235000019136 lipoic acid Nutrition 0.000 claims description 8
- 229960002663 thioctic acid Drugs 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 235000012041 food component Nutrition 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 238000001994 activation Methods 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 230000003278 mimic effect Effects 0.000 claims description 3
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- 235000019750 Crude protein Nutrition 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 210000001772 blood platelet Anatomy 0.000 claims 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 12
- 239000011707 mineral Substances 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 12
- 235000019621 digestibility Nutrition 0.000 abstract description 9
- 230000004060 metabolic process Effects 0.000 abstract description 8
- 230000008236 biological pathway Effects 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 31
- 241000282472 Canis lupus familiaris Species 0.000 description 29
- 239000003925 fat Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 23
- 235000013305 food Nutrition 0.000 description 21
- 108090000994 Catalytic RNA Proteins 0.000 description 20
- 102000053642 Catalytic RNA Human genes 0.000 description 20
- 108091092562 ribozyme Proteins 0.000 description 20
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 239000004615 ingredient Substances 0.000 description 17
- 241000282465 Canis Species 0.000 description 16
- 235000006708 antioxidants Nutrition 0.000 description 16
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 16
- 238000005755 formation reaction Methods 0.000 description 15
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 14
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 14
- 230000037213 diet Effects 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 12
- 239000000654 additive Substances 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 11
- 235000010755 mineral Nutrition 0.000 description 11
- 229940088594 vitamin Drugs 0.000 description 11
- 229930003231 vitamin Natural products 0.000 description 11
- 235000013343 vitamin Nutrition 0.000 description 11
- 239000011782 vitamin Substances 0.000 description 11
- 230000003078 antioxidant effect Effects 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 241000282324 Felis Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 235000021120 animal protein Nutrition 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 229960001231 choline Drugs 0.000 description 7
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 235000019737 Animal fat Nutrition 0.000 description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 230000009109 downstream regulation Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 235000019871 vegetable fat Nutrition 0.000 description 6
- 108010001483 Glycogen Synthase Proteins 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 102000013035 dynein heavy chain Human genes 0.000 description 5
- 108060002430 dynein heavy chain Proteins 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 235000021048 nutrient requirements Nutrition 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000011285 therapeutic regimen Methods 0.000 description 5
- 102000000584 Calmodulin Human genes 0.000 description 4
- 108010041952 Calmodulin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- 108091008103 RNA aptamers Proteins 0.000 description 4
- 108060007030 Ribulose-phosphate 3-epimerase Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 230000004153 glucose metabolism Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 108010021315 integrin beta7 Proteins 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000009107 upstream regulation Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 102000004631 Calcineurin Human genes 0.000 description 3
- 108010042955 Calcineurin Proteins 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000007885 bronchoconstriction Effects 0.000 description 3
- 230000005189 cardiac health Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 244000105975 Antidesma platyphyllum Species 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091012583 BCL2 Proteins 0.000 description 2
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 2
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 2
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101001059662 Homo sapiens Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 2
- 101000772913 Homo sapiens Ubiquitin-conjugating enzyme E2 D3 Proteins 0.000 description 2
- 108010041012 Integrin alpha4 Proteins 0.000 description 2
- 102100033016 Integrin beta-7 Human genes 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 102000004055 Matrix metalloproteinase-19 Human genes 0.000 description 2
- 108090000587 Matrix metalloproteinase-19 Proteins 0.000 description 2
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 2
- 102100031911 NEDD8 Human genes 0.000 description 2
- 108700004934 NEDD8 Proteins 0.000 description 2
- 101150107958 NEDD8 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- 101100532088 Oryza sativa subsp. japonica RUB2 gene Proteins 0.000 description 2
- 101100532090 Oryza sativa subsp. japonica RUB3 gene Proteins 0.000 description 2
- 102000023159 Platelet Glycoprotein GPIb-IX Complex Human genes 0.000 description 2
- 108010045766 Platelet Glycoprotein GPIb-IX Complex Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 241000555745 Sciuridae Species 0.000 description 2
- 102000002938 Thrombospondin Human genes 0.000 description 2
- 108060008245 Thrombospondin Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100030425 Ubiquitin-conjugating enzyme E2 D3 Human genes 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004139 eicosanoid metabolism Effects 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002616 endonucleolytic effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000009424 haa Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000033506 protein kinase C binding proteins Human genes 0.000 description 2
- 108091009576 protein kinase C binding proteins Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 101150024074 rub1 gene Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 102100034278 Annexin A6 Human genes 0.000 description 1
- 108090000656 Annexin A6 Proteins 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 101710116137 Calcium/calmodulin-dependent protein kinase II Proteins 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010036824 Citrate (pro-3S)-lyase Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000005362 Cytoplasmic Dyneins Human genes 0.000 description 1
- 108010070977 Cytoplasmic Dyneins Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- CTZNINKRTKCWGU-UHFFFAOYSA-N Dinactin Natural products CC1C(=O)OC(C)CC(O2)CCC2C(C)C(=O)OC(CC)CC(O2)CCC2C(C)C(=O)OC(CC)CC(O2)CCC2C(C)C(=O)OC(C)CC2CCC1O2 CTZNINKRTKCWGU-UHFFFAOYSA-N 0.000 description 1
- 102100029858 Dipeptidase 2 Human genes 0.000 description 1
- 101710117905 Dipeptidase 2 Proteins 0.000 description 1
- TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 239000004344 EU approved packaging gas Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000289659 Erinaceidae Species 0.000 description 1
- 239000002197 FEMA number Substances 0.000 description 1
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102100029236 Hexokinase-3 Human genes 0.000 description 1
- 101710198398 Hexokinase-3 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 101710122982 Integrin alpha-E Proteins 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000878128 Malleus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- XRYVAQQLDYTHCL-UHFFFAOYSA-N Marini Chemical compound O1C=2C(CC(CC=C(C)C)C(C)=C)=C(O)C=C(O)C=2C(=O)CC1C1=CC=C(O)C=C1O XRYVAQQLDYTHCL-UHFFFAOYSA-N 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 101710143098 Paralytic peptide 1 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 1
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100038394 Platelet glycoprotein VI Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 101710086987 X protein Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940105784 coagulation factor xiii Drugs 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZBDGIMZKOJALMU-MVWQHRGOSA-N dinactin Chemical compound C[C@@H]([C@@H]1CC[C@@H](O1)C[C@@H](OC(=O)[C@@H](C)[C@H]1CC[C@H](O1)C[C@@H](C)OC(=O)[C@@H](C)[C@@H]1CC[C@@H](O1)C[C@H](CC)OC(=O)[C@H]1C)CC)C(=O)O[C@H](C)C[C@@H]2CC[C@H]1O2 ZBDGIMZKOJALMU-MVWQHRGOSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- JPKNLFVGUZRHOB-YUMQZZPRSA-N epsilon-(gamma-glutamyl)lysine Chemical compound OC(=O)[C@@H](N)CCCCNC(=O)CC[C@H](N)C(O)=O JPKNLFVGUZRHOB-YUMQZZPRSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000002331 malleus Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108010064773 platelet membrane glycoprotein VI Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- -1 red Chemical compound 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102000004688 ribulosephosphate 3-epimerase Human genes 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 108091008743 testicular receptors 4 Proteins 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Birds (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/176,331 | 2008-07-18 | ||
| US12/176,331 US8252742B2 (en) | 2004-12-30 | 2008-07-18 | Methods for enhancing the quality of life of a senior animal |
| PCT/US2009/051114 WO2010009458A1 (en) | 2008-07-18 | 2009-07-20 | Methods for enhancing the quality of life of a senior animal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011106036A RU2011106036A (ru) | 2012-08-27 |
| RU2513698C2 true RU2513698C2 (ru) | 2014-04-20 |
Family
ID=41056782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011106036/10A RU2513698C2 (ru) | 2008-07-18 | 2009-07-20 | Способ повышения качества жизни половозрелого животного |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8252742B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2315533A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2011528555A (cg-RX-API-DMAC7.html) |
| CN (2) | CN103766663A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009270702B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0915979A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2731069C (cg-RX-API-DMAC7.html) |
| RU (1) | RU2513698C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010009458A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201101282B (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8252742B2 (en) | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| BRPI0519610A2 (pt) * | 2004-12-30 | 2009-02-25 | Hills Pet Nutrition Inc | mÉtodos para melhorar a qualidade de vida de um animal idoso ou muito idoso, de um canino de raÇa regular ou pequena, idoso ou muito idoso, de um cço de raÇa grande idoso ou muito idoso, e de um gato idoso ou muito idoso |
| US20130059012A1 (en) * | 2010-05-12 | 2013-03-07 | Hill's Pet Nutrition, Inc | Methods for the Diagnosis, Control and Prophylaxis of Inflammation and Mitigation of Inflammatory Conditions in Felines |
| CN102884434B (zh) * | 2010-05-12 | 2015-08-19 | 希尔氏宠物营养品公司 | 用于诊断、控制和预防犬科动物炎症及减轻犬科动物炎性病况的方法 |
| CA2821489A1 (en) * | 2010-12-20 | 2012-06-28 | Hill's Pet Nutrition, Inc. | Pet food compositions for inducing a satiety response |
| EP2705844B1 (en) | 2011-04-13 | 2019-05-22 | Ajinomoto Co., Inc. | Nutritional composition |
| US20130059028A1 (en) * | 2011-09-01 | 2013-03-07 | Julie Marie Foy | Compositions and Methods for Providing a Life-Stage-Appropriate Animal Diet |
| WO2015072972A1 (en) | 2013-11-12 | 2015-05-21 | Hill's Pet Nutrition, Inc. | Improving the level of hydration in a cat |
| AU2015269054A1 (en) * | 2014-06-06 | 2017-01-12 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| CN104026404B (zh) * | 2014-06-10 | 2016-02-24 | 贵州省台江县禹洋农业发展有限公司 | 一种老年期犬粮 |
| US11547125B2 (en) | 2015-02-13 | 2023-01-10 | Mars, Incorporated | Pet food feeding system |
| CN104982668B (zh) * | 2015-07-21 | 2016-08-17 | 广州市优百特饲料科技有限公司 | 一种功能性脂肪粉及其制备方法 |
| GB201522304D0 (en) * | 2015-12-17 | 2016-02-03 | Mars Inc | Food product for reducing muscle breakdown |
| TW201808120A (zh) * | 2016-03-16 | 2018-03-16 | 味之素股份有限公司 | 行動體力提升劑 |
| EP3554268A1 (en) * | 2016-12-15 | 2019-10-23 | Société des Produits Nestlé S.A. | Compositions and methods for small canines |
| BR112019013188B1 (pt) | 2016-12-27 | 2022-12-27 | Hill's Pet Nutrition, Inc. | Composição de alimento para animais domésticos e uso da mesma |
| CA2996780A1 (en) * | 2017-02-28 | 2018-08-28 | Abl Ip Holding Llc | Autonomous electronics platform for light fixtures with integral thermal management properties |
| CN107184598A (zh) * | 2017-04-28 | 2017-09-22 | 深圳市众康动保科技有限公司 | 一种宠物用心脏病复方片剂 |
| GB201721627D0 (en) | 2017-12-21 | 2018-02-07 | Mars Inc | Pet food product |
| WO2024057117A1 (en) * | 2022-09-14 | 2024-03-21 | Societe Des Produits Nestle Sa | Compositions and methods utilizing southern ocean mackerel oil for providing health benefits in an animal |
| CN119894385A (zh) * | 2022-09-30 | 2025-04-25 | 雀巢产品有限公司 | 用于在动物中提供健康益处的方法 |
Family Cites Families (172)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2980716A (en) * | 1954-06-11 | 1961-04-18 | Research Corp | Method for preparing 6, 8-dihalooctanoic esters |
| US3202414A (en) | 1962-01-15 | 1965-08-24 | Gen Motors Corp | Vehicle door actuator |
| US3202514A (en) * | 1963-07-15 | 1965-08-24 | Gen Foods Corp | Animal food and method of making the same |
| US6090414A (en) * | 1970-05-20 | 2000-07-18 | Life Science Labs, Inc. | Method and composition to reduce cancer incidence |
| US3946123A (en) * | 1975-03-10 | 1976-03-23 | Star-Kist Foods, Inc. | Canned pet food |
| US4053647A (en) | 1975-12-12 | 1977-10-11 | Samuel Prussin | Pet food product and process of producing such |
| JPS5519090Y2 (cg-RX-API-DMAC7.html) | 1976-06-14 | 1980-05-06 | ||
| AU524005B2 (en) | 1978-07-05 | 1982-08-26 | Jerky Treats Inc. | Meat containing animal biscuit or kibble |
| US4247562A (en) * | 1978-12-21 | 1981-01-27 | The Quaker Oats Company | Moist pet food with blood chunks and a fluid gravy system |
| JPS57132849A (en) | 1981-02-12 | 1982-08-17 | Sanwa Kagaku Kenkyusho:Kk | Preparation of aseptic health feed |
| JPS57132849U (cg-RX-API-DMAC7.html) | 1981-02-14 | 1982-08-19 | ||
| US5004624A (en) * | 1983-03-14 | 1991-04-02 | Star-Kist Foods, Inc. | Semi-moist pet food having free gravy and process for preparation thereof |
| EP0270690B1 (en) * | 1986-06-21 | 1991-05-15 | Dainippon Ink And Chemicals, Inc. | Drug for treatment and prophylaxis of kidney and liver diseases |
| US5030458A (en) * | 1989-11-27 | 1991-07-09 | Shug Austin L | Method for preventing diet-induced carnitine deficiency in domesticated dogs and cats |
| US4997672A (en) * | 1987-03-10 | 1991-03-05 | Virginia Commonwealth University | Salt taste enhancer |
| ES2043897T3 (es) * | 1988-01-28 | 1994-01-01 | Koeltringer Peter | Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas. |
| US6977167B2 (en) * | 1988-09-07 | 2005-12-20 | Martek Biosciences Corporation | Mixtures of omega-3 and omega-6 highly unsaturated fatty acids from euryhaline microorganisms |
| US4997671A (en) * | 1988-09-09 | 1991-03-05 | Nabisco Brands, Inc. | Chewy dog snacks |
| US5114704A (en) * | 1989-05-30 | 1992-05-19 | Nabisco Brands, Inc. | Raw hide having a coating containing an inorganic pyrophosphate |
| PT95826B (pt) * | 1989-11-09 | 1997-11-28 | Asta Medica Ag | Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico |
| US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| US5419283A (en) * | 1992-04-08 | 1995-05-30 | Ciuffo Gatto S.R.L. | Animal chew toy of starch material and degradable ethylene copolymer |
| US5569670A (en) | 1992-06-05 | 1996-10-29 | Asta Medica Aktiengesellschaft | Combination medications containing alpha-lipoic acid and related |
| US5624896A (en) * | 1992-06-09 | 1997-04-29 | Neorx Corporation | Clearing agents useful in pretargeting methods |
| US5292538A (en) * | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
| DE4235912C2 (de) | 1992-10-23 | 2002-12-05 | Viatris Gmbh | Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung |
| JP3347381B2 (ja) * | 1993-01-27 | 2002-11-20 | 協和醗酵工業株式会社 | ペットフード |
| US5532010A (en) * | 1993-05-28 | 1996-07-02 | Nabisco, Inc. | Coated canine biscuits and preparation process |
| US5339771A (en) * | 1993-09-15 | 1994-08-23 | Axelrod Herbert R | Animal chew toy containing animal meal |
| WO1995013824A1 (en) * | 1993-11-15 | 1995-05-26 | Celtrix Pharmaceuticals, Inc. | Method of treating renal disease by administering igf-i and igfbp-3 |
| CA2147109A1 (en) | 1994-04-18 | 1995-10-19 | Gregory A. Reinhart | Pet food product containing omega-6 and omega-3 fatty acids and process for reducing inflammatory skin responses |
| US7105607B2 (en) * | 1994-04-19 | 2006-09-12 | Applied Elastomerics, Inc. | Tear resistant gels, composites, and articles |
| US6458767B1 (en) | 1994-05-04 | 2002-10-01 | The Uab Research Foundation | Use of peptides inhibitory for thrombospondin dependent TGF-β activation in the treatment of kidney disease |
| DE4427079C2 (de) * | 1994-07-30 | 2002-12-19 | Viatris Gmbh | Verfahren zur Racemisierung von Enantiomeren der alpha-Liponsäure |
| US5976548A (en) | 1994-11-08 | 1999-11-02 | Viva America Marketing, Inc. | Nutritional supplement composition and use |
| US5599835A (en) * | 1994-11-23 | 1997-02-04 | Fischer; Frederick B. | Use of DL-lipoic acid as a medical food in the treatment of diabetes mellitus |
| US5730988A (en) * | 1995-04-20 | 1998-03-24 | Lynntech, Inc. | Nutritional supplements for improving glucose metabolism |
| US6184227B1 (en) * | 1995-07-21 | 2001-02-06 | Savvipharm Inc. | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases |
| FR2738741B1 (fr) * | 1995-09-19 | 1997-12-05 | Oreal | Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p |
| JP3798464B2 (ja) * | 1996-04-09 | 2006-07-19 | 株式会社海洋バイオテクノロジー研究所 | 新規微細藻類及びそれを用いた高度不飽和脂肪酸の製造方法 |
| CA2208392C (en) * | 1996-06-21 | 2002-09-03 | University Of Guelph | Method for enriching docosahexaenoic acid in expressed milk of dairy cattle |
| US5977162A (en) | 1996-09-16 | 1999-11-02 | Seidman; Michael D. | Therapeutic treatment for auditory function |
| CA2269806C (en) * | 1996-10-28 | 2006-01-24 | Bernhard H. Van Lengerich | Embedding and encapsulation of controlled release particles |
| US5976568A (en) | 1997-02-21 | 1999-11-02 | Medical Doctors' Research Institute, Inc. | Modular system of dietary supplement compositions for optimizing health benefits and methods |
| US6232346B1 (en) * | 1997-03-27 | 2001-05-15 | Michael J. Sole | Composition for improvement of cellular nutrition and mitochondrial energetics |
| US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| US6133323A (en) | 1997-04-09 | 2000-10-17 | The Iams Company | Process for enhancing immune response in animals using β-carotene as a dietary supplement |
| US5851573A (en) | 1997-04-29 | 1998-12-22 | The Iams Company | Pet food composition for large breed puppies and method for promoting proper skeletal growth |
| US6264994B1 (en) * | 1997-05-15 | 2001-07-24 | University Of Washington | Compositions for treating alzheimer's disease and other amyloidoses |
| US5883083A (en) * | 1997-06-09 | 1999-03-16 | Harlmen, Inc. | Dietary supplement for alleviating behavioral problems in canines and reducing seizures in canines and felines |
| US5916912A (en) * | 1997-06-16 | 1999-06-29 | The Regents Of The University Of California | Dietary composition for enhancing metabolism and alleviating oxidative stress |
| DE19726519A1 (de) | 1997-06-23 | 1998-12-24 | Asta Medica Ag | Verfahren zur Herstellung trockener Thioctsäure |
| EP0891719A1 (en) | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
| US6039952A (en) | 1997-10-22 | 2000-03-21 | The Iams Company | Composition and method for improving clinical signs in animals with renal disease |
| GB9722361D0 (en) | 1997-10-24 | 1997-12-17 | Pharma Nord Uk Ltd | Pharmaceutical formulation for treating liver disorders |
| US6365623B1 (en) * | 1997-11-17 | 2002-04-02 | Nicholas V. Perricone | Treatment of acne using lipoic acid |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE19810336A1 (de) | 1998-03-11 | 1999-09-23 | Asta Medica Ag | Alpha-Liponsäure mit neuartiger Modifikation |
| US6117477A (en) * | 1998-03-18 | 2000-09-12 | Kal Kan Foods, Inc. | Multicomponent food product and methods of making and using the same |
| US6306430B1 (en) * | 1998-04-16 | 2001-10-23 | The Iams Company | Process for decreasing adiposity using vitamin a as a dietary supplement |
| RU2131677C1 (ru) | 1998-05-05 | 1999-06-20 | Научно-производственная фирма "Аквазинэль" | Кормовая добавка "биовитос" |
| US6492325B1 (en) | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
| US6197340B1 (en) * | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
| JP2000014392A (ja) * | 1998-07-07 | 2000-01-18 | Ikeda Shokken Kk | 高度不飽和脂肪酸含有グリセリドの製造方法 |
| DE19834608A1 (de) * | 1998-07-31 | 2000-02-03 | Basf Ag | Kristallmodifikation der Liponsäure |
| US6136339A (en) | 1998-08-21 | 2000-10-24 | Gardiner; Paul T. | Food supplements and methods comprising lipoic acid and creatine |
| IT1302307B1 (it) * | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil |
| ES2203245T3 (es) * | 1998-09-02 | 2004-04-01 | Heska Corporation | Metodo y composicion para proteger un carnivoro obligado de una enfermedad de metabolismo anormal de carbohidratos. |
| FR2786100B1 (fr) | 1998-11-24 | 2002-03-01 | Aventis Laboratoire | Nouvelle application therapeutique de la nicergoline |
| AUPP784398A0 (en) * | 1998-12-21 | 1999-01-21 | Monash University | Kidney disease detection and treatment |
| US20040029175A1 (en) * | 1998-12-21 | 2004-02-12 | Comper Wayne D. | Method for kidney disease detection |
| IL143892A0 (en) * | 1998-12-21 | 2002-04-21 | Univ Monash | Kidney disease detection and treatment |
| US6284786B1 (en) * | 1999-02-16 | 2001-09-04 | The Center For The Improvement Of Human Functioning, Int'l., Inc. | Treatment of cancer using lipoic acid in combination with ascorbic acid |
| US6238708B1 (en) * | 1999-02-23 | 2001-05-29 | The Iams Company | Composition and process for controlling glucose metabolism in companion animals by dietary starch |
| AUPP887399A0 (en) | 1999-02-24 | 1999-03-25 | Bartlett Grain Pty Ltd | Animal feed formulae for the nutritional enrichment of foodstuffs |
| DE60018225T2 (de) * | 1999-03-01 | 2005-12-29 | Pfizer Products Inc., Groton | Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor |
| IT1306130B1 (it) | 1999-04-16 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti. |
| MXPA01010940A (es) | 1999-05-27 | 2002-07-30 | Iams Company | Proceso y producto para mejorar la respuesta inmunitlaria en animales de compania, usando una combinacion de antioxidantes. |
| US6365211B1 (en) * | 1999-06-18 | 2002-04-02 | The Procter & Gamble Co. | Cooking aid with reduced foaming |
| JP4098927B2 (ja) * | 1999-08-03 | 2008-06-11 | 花王株式会社 | 油脂組成物 |
| AU7828200A (en) | 1999-09-23 | 2001-04-24 | Juvenon Corporation | Nutritional supplement for increased energy and stamina |
| US6426362B1 (en) * | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
| MXPA02004413A (es) * | 1999-11-02 | 2002-09-02 | Depomed Inc | Induccion farmacologica del modo de alimentacion, para la administracion aumentada de drogas al estomago. |
| EP1248609A4 (en) * | 1999-11-03 | 2007-08-01 | Juvenon Inc | METHOD FOR TREATING THE GOOD MEMORY TROUBLESHOOTING |
| NL1013817C2 (nl) * | 1999-12-10 | 2001-06-12 | Stork Mps Bv | Coagulatieoplossing voor het laten coaguleren van een collageen. |
| US6379727B1 (en) * | 1999-12-29 | 2002-04-30 | John F. Addy | Flavoring system for pet foods |
| US20030060503A1 (en) * | 2000-01-25 | 2003-03-27 | Juvenon, Inc. | Nutritional supplements for mature pets |
| JP2003529347A (ja) * | 2000-01-25 | 2003-10-07 | ジュヴェノン インコーポレイテッド | 高齢ペット用の栄養補給食品 |
| US20020006907A1 (en) * | 2000-02-01 | 2002-01-17 | Paul Gardiner | Alpha lipoic acid based food supplement for increasing lean muscle mass and strength |
| EG22407A (en) * | 2000-02-17 | 2003-01-29 | Iams Company | Method for improving bone modeling and chondrocyte functioning in growing canines |
| CO5280054A1 (es) | 2000-03-22 | 2003-05-30 | Nestle Sa | Alimento para mascotas dentalmente beneficioso y su metodo de fabricacion |
| JP4487376B2 (ja) * | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| EP1155627A1 (en) | 2000-05-18 | 2001-11-21 | Belovo Eggs & Egg Products | Eggs with balanced lipid composition |
| US6436463B1 (en) * | 2000-06-26 | 2002-08-20 | Hill's Pet Nutrition, Inc. | Pet food composition and method |
| WO2002013624A1 (en) | 2000-08-10 | 2002-02-21 | Renessen Llc | Products comprising corn oil and corn meal obtained from high oil corn |
| US20020044988A1 (en) | 2000-08-22 | 2002-04-18 | Fuchs Eileen C. | Nutritional composition and method for improving protein deposition |
| WO2002019839A1 (en) * | 2000-09-07 | 2002-03-14 | University Of Maryland Biotechnology Institute | Use of arachidonic acid for enhanced culturing of fish larvae and broodstock |
| US6784159B2 (en) * | 2000-09-29 | 2004-08-31 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture | Triterpene saponins from soybeans for treating kidney disease |
| US6277842B1 (en) * | 2000-10-17 | 2001-08-21 | James Alexander Carthron | Dietary supplemental method for fat and weight reduction |
| US8592479B2 (en) * | 2000-10-31 | 2013-11-26 | Hill's Pet Nutrition, Inc. | Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals |
| US8669282B2 (en) * | 2000-10-31 | 2014-03-11 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
| US20020076470A1 (en) * | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
| US20020115710A1 (en) * | 2000-10-31 | 2002-08-22 | Zicker Steven Curtis | Composition and method |
| US20090156658A1 (en) * | 2000-10-31 | 2009-06-18 | Hill's Pet Nutrition, Inc. | Antioxidant-Containing Food Composition For Use In Inhibiting Histamine Pathways In Companion Animals |
| US20020076469A1 (en) * | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
| US20020052402A1 (en) * | 2000-10-31 | 2002-05-02 | Colgate-Palmolive Company | Composition and method |
| EP1345500B1 (en) * | 2000-12-29 | 2008-07-30 | Martin Francis Gannon | An animal food product |
| WO2002071874A2 (en) * | 2001-03-09 | 2002-09-19 | Societe Des Produits Nestle S.A. | Composition improving age-related physiological deficits and increasing longevity |
| US7001610B2 (en) | 2001-04-23 | 2006-02-21 | Omeganutrel Inc. | Food supplement and use thereof for elevating levels of essential fatty acids in livestock and products therefrom |
| US6716460B2 (en) * | 2001-05-14 | 2004-04-06 | Martek Biosciences Corporation | Method of improving the flavor, tenderness and overall consumer acceptability of poultry meat |
| US6596762B2 (en) * | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
| US6596768B2 (en) * | 2001-05-22 | 2003-07-22 | Church & Dwight Co., Inc. | Unsaturated lipid-enriched feedstock for ruminants |
| US6902739B2 (en) * | 2001-07-23 | 2005-06-07 | Nutracea | Methods for treating joint inflammation, pain, and loss of mobility |
| GB0119052D0 (en) * | 2001-08-03 | 2001-09-26 | Mars Uk Ltd | Foodstuff |
| US6923960B2 (en) * | 2001-10-03 | 2005-08-02 | Vsl Pharmaceuticals Inc. | Antioxidant combination composition and use thereof |
| GB0129864D0 (en) | 2001-12-13 | 2002-02-06 | Danisco | Animal feed |
| US20030190343A1 (en) * | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
| ES2355890T3 (es) | 2002-04-05 | 2011-04-01 | Societe des Produits Nestlé S.A. | Composiciones y métodos para promocionar la asimilación de lípidos en los animales domésticos. |
| US20030194478A1 (en) | 2002-04-12 | 2003-10-16 | Davenport Gary Mitchell | Dietary methods for canine performance enhancement |
| US6733793B2 (en) | 2002-06-04 | 2004-05-11 | Metaproteomics, Llc | Oral composition with insulin-like activities and methods of use |
| US6572899B1 (en) * | 2002-07-03 | 2003-06-03 | Vitacost.Com, Inc. | Memory loss treatment formulation |
| CN1309813C (zh) | 2002-08-07 | 2007-04-11 | 花王株式会社 | 油脂组合物 |
| JP2004141130A (ja) | 2002-08-28 | 2004-05-20 | Mars Inc | 特定の犬種に専用のドッグフード |
| WO2004028469A2 (en) | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Docohexaenoic acid for improved glycemic control |
| US6974841B1 (en) | 2002-09-27 | 2005-12-13 | Rapisarda Family Irrevocable Trust | Pet anti-aging wellness supplement |
| US8841344B2 (en) * | 2002-10-03 | 2014-09-23 | Hill's Pet Nutrition, Inc. | Method of using omega-3 fatty acids |
| JP3813585B2 (ja) * | 2003-01-23 | 2006-08-23 | 花王株式会社 | ジグリセリドの製造方法 |
| RU2221456C1 (ru) | 2003-03-11 | 2004-01-20 | Общество с ограниченной ответственностью "Арсентех" | Биологически активное вещество, биологически активная добавка к пище, фармацевтический препарат, биологически активная добавка для кормления животных, ветеринарный препарат, удобрение, активатор микробиологических процессов, пероральное питание, парфюмерно-косметическое средство, гигиеническое средство, молочный продукт, кондитерское изделие, хлебобулочное изделие, масло-жировой продукт, соус, алкогольный напиток, безалкогольный напиток, рыбный продукт, мясной продукт, макаронные изделия, жевательная резинка, пиво |
| EP1633768A2 (en) * | 2003-05-13 | 2006-03-15 | The Regents Of The University Of Colorado | Diagnostic and therapeutic treatments related to mitochondrial disorders |
| US7202270B2 (en) * | 2003-06-20 | 2007-04-10 | Sami Labs Limited | Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses |
| WO2005006877A1 (en) * | 2003-07-03 | 2005-01-27 | Hill's Pet Nutrition, Inc. | Compositions and methods for decreasing age-related deterioration in metal activities in companion animals |
| US8633247B2 (en) * | 2003-08-11 | 2014-01-21 | Hill's Pet Nutrition, Inc. | Method for decreasing cartilage damage in dogs |
| US20060280776A1 (en) * | 2003-09-02 | 2006-12-14 | Masafumi Koide | Diet food |
| US7078064B2 (en) * | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
| ITMI20040069A1 (it) * | 2004-01-21 | 2004-04-21 | Tiberio Bruzzese | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
| WO2005099478A1 (en) | 2004-04-16 | 2005-10-27 | Nestec S.A. | Method and compositions for reducing oxidative stress in an animal |
| US20050266051A1 (en) | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
| US20060002985A1 (en) * | 2004-07-02 | 2006-01-05 | Zicker Steven C | Compositions and methods for decreasing age-related deterioration in mental activities in companion animals |
| CA2578634C (en) * | 2004-08-30 | 2016-06-14 | Hill's Pet Nutrition, Inc. | Genome-based diet design |
| CN101098623B (zh) * | 2004-11-09 | 2012-10-10 | 希尔氏宠物营养品公司 | 抗氧化剂用于基因调节的用途 |
| EP1817022B1 (en) | 2004-11-24 | 2018-04-25 | Hill's Pet Nutrition, Inc. | Methods for increasing the immune response in an animal |
| CN104055764A (zh) * | 2004-11-24 | 2014-09-24 | 希尔氏宠物营养品公司 | 改进动物异生素物质肝清除率的方法 |
| US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
| US8168161B2 (en) | 2004-12-22 | 2012-05-01 | Hill's Pet Nutrition, Inc. | Method to promote oral health in companion animals |
| ES2436181T3 (es) * | 2004-12-29 | 2013-12-27 | Hill's Pet Nutrition Inc. | Métodos para inhibir un declive en el aprendizaje y/o la memoria en animales |
| US8647660B2 (en) * | 2004-12-29 | 2014-02-11 | Hill's Pet Nutrition, Inc. | Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health |
| US7700139B2 (en) * | 2004-12-30 | 2010-04-20 | Commonwealth Scientific And Industrial Research Organization | Method and means for improving bowel health |
| US8252742B2 (en) | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| BRPI0519610A2 (pt) * | 2004-12-30 | 2009-02-25 | Hills Pet Nutrition Inc | mÉtodos para melhorar a qualidade de vida de um animal idoso ou muito idoso, de um canino de raÇa regular ou pequena, idoso ou muito idoso, de um cço de raÇa grande idoso ou muito idoso, e de um gato idoso ou muito idoso |
| CN101128124A (zh) * | 2004-12-30 | 2008-02-20 | 希尔氏宠物营养品公司 | 用于猫消费的组合物 |
| CA2598525A1 (en) * | 2005-02-22 | 2006-08-31 | Mochida Pharmaceutical Co., Ltd. | Nerve regeneration promoting agent |
| WO2006117668A1 (en) * | 2005-05-04 | 2006-11-09 | Pronova Biopharma Norge As | Fatty acid analogues, i.e. dha derivatives for uses as a medicament |
| AU2006263652B2 (en) * | 2005-06-29 | 2010-06-17 | Hill's Pet Nutrition, Inc. | Methods and compositions for the prevention and treatment of inflammatory disease |
| BRPI0613000A2 (pt) * | 2005-07-14 | 2012-12-04 | Hills Pet Nutrition Inc | método para aumentar a longevidade de um animal, artigo de fabricação, kit, e, meio de comunicação de informação acerca de ou instruções para a administração a um animal velho de uma composição |
| JP4903796B2 (ja) * | 2005-08-17 | 2012-03-28 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 腎疾患の予防及び治療のための方法及び組成物 |
| CA2623266C (en) * | 2005-09-20 | 2018-08-21 | J.R. Simplot Company | Low acrylamide foods and their production comprising reduction of asparagine levels in plants |
| CA2627498C (en) | 2005-11-10 | 2013-06-11 | Hill's Pet Nutrition, Inc. | Compositions and methods for improving skin health and pelage quality |
| WO2007062325A1 (en) * | 2005-11-18 | 2007-05-31 | Hill's Pet Nutrition, Inc. | Methods for reducing the amount of proinflammatory substance in animal tissue or body fluid |
| WO2007069900A1 (en) * | 2005-12-16 | 2007-06-21 | N.V. Nutricia | Use of soluble dietary fibres against muscle wasting |
| EP1968567B1 (en) * | 2005-12-20 | 2014-06-18 | Cenestra, Llc | Omega 3 fatty acid formulations |
| ES2384701T3 (es) * | 2005-12-21 | 2014-07-02 | Brudy Technology, S.L. | Utilización del DHA para el tratamiento de una patología asociada con el daño celular oxidativo |
| WO2007088046A2 (en) * | 2006-02-01 | 2007-08-09 | Nestec S.A. | Nutritional system and methods for increasing longevity |
| FR2903860B1 (fr) * | 2006-07-21 | 2010-12-31 | Royal Canin Sa | Aliment sec pour reduire l'appetit des chiens |
| US20080076823A1 (en) * | 2006-08-09 | 2008-03-27 | Watkins Bruce A | Methods of improving bone health and muscle health |
| US7282225B1 (en) | 2006-09-27 | 2007-10-16 | Occular Technologies, Inc. | Composition and methods for improving retinal health |
| US20090093441A1 (en) * | 2006-10-20 | 2009-04-09 | Lynch Stephanie K | Preventing or reducing oxidative stress or oxidative cell injury |
| WO2008151131A1 (en) | 2007-06-04 | 2008-12-11 | Mane, Inc. | Palatability enhancing compositions and foods for pets, and methods regarding the same |
| US20080317725A1 (en) | 2007-06-20 | 2008-12-25 | Baum Seth J | Compositions and methods of treating chronic kidney disease |
| US20080317884A1 (en) | 2007-06-22 | 2008-12-25 | Jewell Dennis E | Enhancing Disease Resistance In An Animal |
| WO2009067530A1 (en) * | 2007-11-20 | 2009-05-28 | Albion International Inc. | Increased protein or energy digestion resulting from inclusion of metal amino acid chelates in animal feed |
| RU2500402C2 (ru) | 2008-01-04 | 2013-12-10 | Нестек С.А. | Композиции, включающие ненасыщенные жирные кислоты и соединения, высбождающие оксид азота, и их применение для усиления когнитивной функции и связанных с ней функций |
| CA2731088C (en) * | 2008-07-18 | 2015-09-22 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
-
2008
- 2008-07-18 US US12/176,331 patent/US8252742B2/en active Active
-
2009
- 2009-07-20 EP EP09790624A patent/EP2315533A1/en not_active Ceased
- 2009-07-20 RU RU2011106036/10A patent/RU2513698C2/ru not_active IP Right Cessation
- 2009-07-20 CA CA2731069A patent/CA2731069C/en not_active Expired - Fee Related
- 2009-07-20 EP EP16174970.0A patent/EP3155904B1/en active Active
- 2009-07-20 CN CN201410049648.8A patent/CN103766663A/zh active Pending
- 2009-07-20 BR BRPI0915979A patent/BRPI0915979A8/pt not_active Application Discontinuation
- 2009-07-20 CN CN200980137379.8A patent/CN102186359B/zh not_active Expired - Fee Related
- 2009-07-20 AU AU2009270702A patent/AU2009270702B2/en not_active Ceased
- 2009-07-20 WO PCT/US2009/051114 patent/WO2010009458A1/en not_active Ceased
- 2009-07-20 JP JP2011518956A patent/JP2011528555A/ja active Pending
-
2011
- 2011-02-17 ZA ZA2011/01282A patent/ZA201101282B/en unknown
-
2012
- 2012-07-24 US US13/556,925 patent/US8669211B2/en not_active Expired - Lifetime
-
2013
- 2013-09-24 US US14/035,287 patent/US8759283B2/en not_active Expired - Lifetime
-
2014
- 2014-12-18 JP JP2014255730A patent/JP6178302B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20120289430A1 (en) | 2012-11-15 |
| JP2011528555A (ja) | 2011-11-24 |
| EP3155904A2 (en) | 2017-04-19 |
| US20090111877A1 (en) | 2009-04-30 |
| AU2009270702A1 (en) | 2010-01-21 |
| EP3155904B1 (en) | 2024-09-18 |
| JP2015077139A (ja) | 2015-04-23 |
| AU2009270702B2 (en) | 2012-11-15 |
| BRPI0915979A8 (pt) | 2017-10-10 |
| CN102186359B (zh) | 2016-03-23 |
| RU2011106036A (ru) | 2012-08-27 |
| US8669211B2 (en) | 2014-03-11 |
| US20140018528A1 (en) | 2014-01-16 |
| CN102186359A (zh) | 2011-09-14 |
| CA2731069C (en) | 2015-10-27 |
| ZA201101282B (en) | 2014-07-30 |
| US8759283B2 (en) | 2014-06-24 |
| BRPI0915979A2 (pt) | 2015-08-11 |
| US8252742B2 (en) | 2012-08-28 |
| WO2010009458A1 (en) | 2010-01-21 |
| JP6178302B2 (ja) | 2017-08-09 |
| CA2731069A1 (en) | 2010-01-21 |
| EP2315533A1 (en) | 2011-05-04 |
| EP3155904A3 (en) | 2017-06-28 |
| CN103766663A (zh) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2513698C2 (ru) | Способ повышения качества жизни половозрелого животного | |
| RU2525617C2 (ru) | Способ модулирования биологических функций, ассоциированных с процессом старения пожилого или старого животного-компаньона. | |
| Buff et al. | Natural pet food: A review of natural diets and their impact on canine and feline physiology | |
| Benítez et al. | Nutrigenomics in farm animals | |
| dos Santos Fontes et al. | Intramuscular collagen characteristics and expression of related genes in skeletal muscle of cull cows receiving a high-energy diet | |
| ES2954279T3 (es) | Composiciones y métodos que modulan el fósforo o las enzimas en un animal de compañía | |
| Yang et al. | Transcriptomic and biochemical analyses revealed the improved growth, lipid metabolism, and flesh quality of grass carp (Ctenopharyngodon idellus) by dietary Eucommia ulmoides bark and leaf supplementation | |
| Shi et al. | The effect of dietary folic acid on flesh quality and muscle antioxidant status referring to Nrf2 signalling pathway in young grass carp (Ctenopharyngodon idella) | |
| Chen et al. | Estimation of dietary selenium requirement for Chinese egg-laying ducks | |
| AU2013200758B2 (en) | Methods for enhancing the quality of life of a senior animal | |
| Zhai et al. | Effects of lactic acid bacteria on protein metabolism of Sunit lamb | |
| Wen et al. | Effects of dietary thiamin on flesh quality in grass carp (Ctenopharyngodon idella) | |
| El-Sayed | Effect of Dietary Supplementation of Nannochloropsis on Gene Expression and Serum Profile of Metabolic and Lipogenic Markers in Growing Barki Lambs | |
| CA2862200A1 (en) | Methods for enhancing the quality of life of a senior animal | |
| Baggerman | ROLE OF ENCAPSULATED AMINO ACIDS ON SKELETAL MUSCLE GROWTH AND DEVELOPMENT IN FEEDLOT STEERS | |
| 平川泰子 | Comparative biochemistry studies of the energy metabolism in large animals | |
| Baggerman | Role of encapsulated amino acids on post-natal skeletal muscle growth and development in feedlot steers | |
| Hocquette et al. | Contribution of'Omics' Approaches to Sustainable Herbivore Production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180721 |